AprilBio

397030 · KOSDAQ · South Korea

Public Market Listing

397030KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for AprilBio are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
IL-18Protein / enzyme therapeutic
Atopic Dermatitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 February 2026Topline resultEVO301Phase 2a proof-of-concept trial of EVO301 in atopic dermatitis met its primary endpoint
Evommune · Source ↗

Financial reports

No financial reports recorded.